SEC Form 10-K filed by Pershing Square Tontine Holdings Ltd.
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
I.R.S. Employer Identification Number) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
share of Class A Common Stock at an exercise price of $23.00 |
☒ |
Accelerated filer |
☐ | ||||
Non-accelerated filer |
☐ |
Smaller reporting company |
||||
Emerging growth company |
Auditor Firm ID: |
Auditor Name: |
Auditor Location: |
Page |
||||||
1 |
||||||
PART I |
||||||
ITEM 1. |
4 |
|||||
ITEM 1A. |
20 |
|||||
ITEM 1B. |
49 |
|||||
ITEM 2. |
49 |
|||||
ITEM 3. |
49 |
|||||
ITEM 4. |
49 |
|||||
PART II |
||||||
ITEM 5. |
50 |
|||||
ITEM 6. |
51 |
|||||
ITEM 7. |
51 |
|||||
ITEM 7A. |
57 |
|||||
ITEM 8. |
57 |
|||||
ITEM 9. |
57 |
|||||
ITEM 9A. |
57 |
|||||
ITEM 9B. |
59 |
|||||
PART III |
||||||
ITEM 10. |
59 |
|||||
ITEM 11. |
65 |
|||||
ITEM 12. |
65 |
|||||
ITEM 13. |
67 |
|||||
ITEM 14. |
71 |
|||||
PART IV |
||||||
ITEM 15. |
72 |
|||||
ITEM 16. |
74 |
|||||
75 |
• | our ability to select an appropriate target business or businesses; |
• | our ability to complete our initial business combination, particularly in light of disruption that may result from limitations imposed by the COVID-19 pandemic and existing litigation alleging that we are required to register as an investment company; |
• | our expectations around the performance of the prospective target business or businesses; |
• | our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
• | our management team and investment team members allocating their time to other businesses, and our directors and officers potentially having conflicts of interest with our business or in approving our initial business combination, as a result of which they would then receive expense reimbursements; |
• | our potential ability to obtain additional financing to complete our initial business combination; |
• | our pool of prospective target businesses; |
• | the ability of our directors and officers to generate a number of potential acquisition opportunities; |
• | our public securities’ potential liquidity and trading; |
• | the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; |
• | the trust account not being subject to claims of third parties; or |
• | our financial performance. |
• | “Additional Forward Purchase Units” are to the up to 100,000,000 units (or such greater amount as determined by mutual agreement of the company and the Forward Purchasers), each consisting of one share of Class A Common Stock and one-third of one warrant, that the Forward Purchasers may elect to purchase pursuant to the Forward Purchase Agreement; |
• | “amended and restated certificate of incorporation” are to our second amended and restated certificate of incorporation; |
• | “Affiliate Transferees” are to any entity that is managed by PSCM; |
• | “company”, “our company”, “we” or “us”, are to Pershing Square Tontine Holdings, Ltd.; |
• | “common stock” are to our Class A Common Stock and our Class B Common Stock, collectively; |
• | “common shares” are to the common stock, membership interests, units or other equity security of the continuing publicly traded corporation following our initial business combination, if such post-combination business is not the company, and to our Class A Common Stock if we are the continuing publicly traded corporation following our initial business combination; |
• | “Committed Forward Purchase Units” are to the 50,000,000 units, each consisting of one share of Class A Common Stock and one-third of one Redeemable Warrant, that the Forward Purchasers have committed to purchase pursuant to the Forward Purchase Agreement; |
• | “Director Forward Purchase Agreement” are to an agreement providing for the sale of an aggregate amount of $6,000,000 of our Forward Purchase Units to certain of our independent directors, in one or more private placements in such amounts and at such time or times as the Director Forward Purchasers determine, but no later than simultaneously with the closing of our initial business combination; |
• | “Director Forward Purchase Units” are to the Forward Purchase Units to be purchased by certain of our independent directors pursuant to the Director Forward Purchase Agreement; |
• | “Director Forward Purchasers” are to those of our independent directors who are party to the Director Forward Purchase Agreement and have agreed to purchase our Forward Purchase Units pursuant thereto; |
• | “Director Warrants” are to the warrants purchased by our directors, other than Mr. Ackman, in private placements which closed simultaneously with the initial public offering, for an aggregate amount of $2,837,500, which will be exercisable for 0.26% of the common shares of the post-combination business (on a fully diluted basis), at an exercise price of $24.00 per common share of the post-combination business. The Director Warrants will have a term of 10 years from the consummation of our initial business combination and subject to certain transfer restrictions and have certain registration rights, and otherwise have terms identical to those of the Sponsor Warrants; |
• | “Distributable Redeemable Warrants” are to the warrants issuable upon exercise of the Redeemable Warrants attached to each unit issued in the initial public offering. |
• | “Distributable Tontine Redeemable Warrants” are to the warrants issuable in respect of those Public Shares that have not been redeemed in connection with our initial business combination; |
• | “Forward Purchase Agreement” are to an agreement providing for the sale of our Forward Purchase Units to the Pershing Square Funds (in their capacity as the Forward Purchasers) or, in the case of the Additional Forward Purchase Units, to the Affiliate Transferees, in one or more private placements in such amounts and at such time or times as the Forward Purchasers determine, but no later than simultaneously with the closing of our initial business combination; |
• | “Forward Purchase Securities” are to the Forward Purchase Shares, Forward Purchase Warrants, and shares of Class A Common Stock underlying the Forward Purchase Warrants; |
• | “Forward Purchase Shares” are to the shares of Class A Common Stock to be issued pursuant to the Forward Purchase Agreement and to certain directors purchasing Director Forward Purchase Units, which will generally have identical terms to those of the shares of Class A Common Stock issued in the initial public offering, except as described herein; |
• | “Forward Purchase Warrants” are to the warrants to be issued pursuant to the Forward Purchase Agreement and to certain directors purchasing Director Forward Purchase Units, which will generally have identical terms to those of the Redeemable Warrants issued in the initial public offering, except as described herein; |
• | “Forward Purchase Units” are to the Committed Forward Purchase Units and the Additional Forward Purchase Units issuable pursuant to the Forward Purchase Agreement, and the Director Forward Purchase Units issuable to the Director Forward Purchasers; |
• | “Forward Purchasers” are to the Pershing Square Funds and, for the avoidance of doubt, such term does not include the Director Forward Purchasers; |
• | “Initial Business Combination Redemption Time” are to the time at which we redeem the shares of Class A Common Stock that the holders thereof have elected to redeem in connection with our initial business combination, which will occur prior to the consummation our initial business combination; |
• | “Pershing Square” or “PSCM” are to Pershing Square Capital Management, L.P., a registered investment adviser under the Investment Advisers Act of 1940. |
• | “Pershing Square Funds” are to Pershing Square, L.P., a Delaware limited partnership, Pershing Square International, Ltd., a Cayman Islands exempted company, and Pershing Square Holdings, Ltd., a Guernsey company, which funds are managed by PSCM and are, collectively, the members of our Sponsor and the Forward Purchasers; |
• | “Public Shares” are to the shares of Class A Common Stock included in the units issued in the initial public offering; |
• | “Public Stockholders” are to the holders of the Public Shares, including our Sponsor and its affiliates and our management team, to the extent that such persons or entities acquire Public Shares (whether during or after the initial public offering), provided that such status as a “Public Stockholder” shall only exist with respect to such shares; |
• | “Redeemable Warrants” are to our Distributable Redeemable Warrants included in the units issued in the initial public offering and to the Distributable Tontine Redeemable Warrants issuable to the remaining holders of our outstanding shares of our Class A Common Stock issued in the initial public offering (after we redeem any shares of Class A Common Stock that the holders thereof have elected to redeem in connection with our initial business combination), and, for the avoidance of doubt, the term “Redeemable Warrants” does not include the Forward Purchase Warrants; |
• | “Registration Rights Agreement” are to an agreement requiring the company, following our initial business combination, to register for resale certain securities held by our Sponsor, directors, the Forward Purchasers and their permitted transferees; |
• | “Sponsor” are to Pershing Square TH Sponsor, LLC, a Delaware limited liability company; |
• | “Sponsor Warrants” are to the warrants purchased by our Sponsor in a private placement simultaneously with the initial public offering that will generally not be salable, transferable or exercisable until three years after the date of our initial business combination, and will only then be exercisable for that number of common shares constituting 5.95% of the common shares of the post-combination business on a fully diluted basis as of the time immediately following our initial business combination, at an exercise price equal to $24.00 per common share of the post-combination business. The Sponsor Warrants will have a term of 10 years from the consummation of our initial business combination; |
• | “Tontine Distribution Time” are to the time at which the Distributable Tontine Redeemable Warrants will be distributed, which will occur immediately after our initial business combination Redemption Time and immediately prior to the closing of our initial business combination; and |
• | “Warrants” are to our Redeemable Warrant, Forward Purchase Warrant, Sponsor Warrants and our Director Warrants, collectively. |
• | The Company and the Pershing Square Funds agreed to amend and restate the Forward Purchase Agreement concurrently with the closing of the Proposed IBC, pursuant to which the Forward Purchasers would exercise their right to purchase an aggregate amount of $1.6 billion of Forward Purchase Units ($1.0 billion of Committed Forward Purchase Units and $600 million of Additional Forward Purchase Units). The price per share at which the Pershing Square Funds would have exercised such amended Forward Purchase Agreement would be equal to RemainCo’s (defined below) net asset value at the time of such purchase; |
• | The Company and the Sponsor agreed to amend the Sponsor Warrants concurrently with the closing of the Proposed IBC, such that the Sponsor Warrants would not be exercised or otherwise participate in the Proposed IBC. Instead, they would remain in place, but the exercise price would be adjusted to equal 120% of RemainCo’s net asset value immediately prior to the time it completed its anticipated future business combination with an operating business; and |
• | The Company and its independent directors agreed that the Director Warrants would not be exercised in connection with the Proposed IBC, and would be amended concurrently with the closing of the Proposed IBC. The result of such amendment would have been that, (i) the holders of the Director Warrants would receive shares in the Company in exchange for approximately 72% of the fair market value of the Director Warrants (as determined by a third-party valuation firm), to compensate for the fact that they would not participate in the Proposed IBC as originally envisioned, (ii) such shares would participate in the Distribution and (iii) the roughly 28% of the value of the Director Warrants would remain in place with their exercise price adjusted in the same manner as the exercise price of the Sponsor Warrants as explained above. |
• | Simple, predictable, and free-cash-flow-generative. |
• | Formidable barriers to entry. |
• | Limited exposure to extrinsic factors that we cannot control |
• | Strong balance sheet de-leveraging effects of the Initial Business Combination; |
• | Minimal capital markets dependency |
• | Large capitalization |
• | Attractive valuation |
• | Exceptional management and governance |
Dilution from Sponsor and Director Warrants to Public Holders | ||||||||||
Share Price of our Class A Common Stock |
Post-Combination Business Equity Value at IBC (in millions) | |||||||||
$10,000 |
$15,000 |
$20,000 |
$25,000 |
$30,000 | ||||||
% Public Holders Equity Ownership Stake at IBC | ||||||||||
40.0% |
26.7% |
20.0% |
16.0% |
13.3% | ||||||
$20.00 |
— | — | — | — | — | |||||
$24.00 |
— | — | — | — | — | |||||
$28.00 |
1.1% | 1.0% | 1.0% | 1.0% | 1.0% | |||||
$32.00 |
1.8% | 1.8% | 1.7% | 1.7% | 1.7% | |||||
$36.00 |
2.4% | 2.3% | 2.3% | 2.2% | 2.2% |
• | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our Initial Business Combination, and |
• | cause us to depend on the marketing and sale of a single product or limited number of products or services. |
Type of Transaction |
Whether Stockholder Approval is Required | |
Purchase of assets |
No | |
Purchase of stock of target not involving a merger with the company |
No | |
Merger of target into a subsidiary of the company |
No | |
Merger of the company with a target |
Yes |
• | we issue common stock that will be equal to or in excess of 20% of the number of shares of our Class A Common Stock then outstanding (other than in a public offering); |
• | any of our directors, officers or substantial security holders (as defined by NYSE rules) has a 5% or greater interest, directly or indirectly, in the target business or assets to be acquired and the number of shares or common stock to be issued, or if the number of shares into which the securities may be convertible or exercisable, exceeds either (a) 1% of the number of shares of common stock or 1% of the voting power outstanding before the issuance in the case of any of our directors and officers or (b) 5% of the number of shares of common stock or 5% of the voting power outstanding before the issuance in the case of any substantial security holders; or |
• | the issuance or potential issuance of common stock will result in our undergoing a change of control (as defined by NYSE rules). |
• | conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and |
• | file tender offer documents with the SEC prior to completing our Initial Business Combination which contain substantially the same financial and other information about our Initial Business Combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies. |
• | conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules, and |
• | file proxy materials with the SEC. |
• | Our Public Stockholders may not be afforded an opportunity to vote on our proposed Initial Business Combination, which means we may complete our Initial Business Combination even though a majority of our Public Stockholders do not support such a combination. |
• | If we seek stockholder approval of our Initial Business Combination, our Sponsor, directors, officers and Forward Purchasers have agreed to vote in favor of such Initial Business Combination, regardless of how our Public Stockholders vote. |
• | Your only opportunity to affect the investment decision regarding a potential business combination will be limited to the exercise of your right to redeem your shares from us for cash, unless we seek stockholder approval of our Initial Business Combination. |
• | The ability of our Public Stockholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into a business combination with a target in a timely fashion within the Combination Period. |
• | The ability of our Public Stockholders to exercise redemption rights with respect to a large number of our shares may not allow us to complete the most desirable business combination or optimize our capital structure. |
• | The ability of our Public Stockholders to exercise redemption rights with respect to a large number of our shares could increase the probability that our Initial Business Combination would be unsuccessful and that you would have to wait for liquidation in order to redeem your stock. |
• | The requirement that we complete our Initial Business Combination within the Combination Period may give potential target businesses leverage over us in negotiating our Initial Business Combination and may decrease our ability to conduct due diligence on potential business combination targets, in particular, as we approach our dissolution deadline, which could undermine our ability to complete our Initial Business Combination on terms that would produce value for our Public Stockholders. |
• | We may not be able to complete our Initial Business Combination within the prescribed timeframe, in which case we would cease all operations except for the purpose of winding up and we would redeem our Public Shares and liquidate, in which case our Public Stockholders may only receive $20.00 per share and our Distributable Redeemable Warrants, Sponsor Warrants and Director Warrants will expire worthless, and our Distributable Tontine Redeemable Warrants will never have been distributed. |
• | If a stockholder fails to receive notice of our offer to redeem our Public Shares in connection with our Initial Business Combination, or fails to comply with the procedures for tendering its shares, such shares may not be redeemed. |
• | We may, but are not required to, obtain an opinion from an independent investment banking firm or from an independent accounting firm, and consequently, you may have no assurance from an independent source that the price we are paying for the business is fair to our company from a financial point of view. |
• | We may only be able to complete one business combination with the proceeds of the initial public offering, the sale of the Forward Purchase Units and the sale of the Sponsor Warrants and Director Warrants, which will cause us to be solely dependent on a single business which may have a limited number of products or services and limited operating activities. This lack of diversification may negatively impact our operating results and profitability. |
• | Members of our management team and investment team will allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on our ability to complete our Initial Business Combination. |
• | Certain of our directors and officers are now, and all of them may in the future become, affiliated with entities engaged in business activities similar to those intended to be conducted by us and, accordingly, may have conflicts of interest in allocating their time and determining to which entity a particular business opportunity should be presented. |
• | Since the Forward Purchasers, our Sponsor and directors will lose the investment opportunity presented by the Forward Purchase Units, the Sponsor Warrants and Director Warrants, respectively, if our Initial Business Combination is not |
completed, our Sponsor and directors may have a conflict of interest in determining whether a particular business combination target is appropriate for our Initial Business Combination. |
• | We face litigation claiming that we were required to register as an investment company under the Investment Company Act of 1940 which may, even if meritless make it difficult for us to enter into a business combination with a target in a timely fashion within the Combination Period. |
• | a limited availability of market quotations for our securities; |
• | reduced liquidity for our securities; |
• | a determination that our Class A Common Stock is a “penny stock,” which will require brokers trading in our Class A Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; |
• | a limited amount of news and analyst coverage; and |
• | a decreased ability to issue additional securities or obtain additional financing in the future. |
• | restrictions on the nature of our investments; and |
• | restrictions on the issuance of securities, |
• | registration as an investment company; |
• | adoption of a specific form of corporate structure; and |
• | reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations. |
• | may significantly dilute the equity interest of our stockholders; |
• | may subordinate the rights of holders of common stock if preferred stock is issued with rights senior to those afforded our common stock; |
• | could cause a change of control if a substantial number of shares of our common stock are issued, which may affect, among other things, our ability to use net operating loss carry forwards, if any, and could result in the resignation or removal of our present directors and officers; and |
• | may adversely affect prevailing market prices for our Class A Common Stock and/or Redeemable Warrants. |
• | default and foreclosure on our assets if our operating revenues after our Initial Business Combination are insufficient to repay our debt obligations; |
• | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
• | our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand; |
• | our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding; |
• | our inability to pay dividends on our common stock; |
• | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, our ability to pay expenses, make capital expenditures and acquisitions, and fund other general corporate purposes; |
• | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
• | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; |
• | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, and execution of our strategy; and |
• | other disadvantages compared to our competitors who have less debt. |
• | the history and prospects of companies whose principal business is the acquisition of other companies; |
• | prior offerings of those companies; |
• | our prospects for acquiring an operating business; |
• | a review of debt to equity ratios in leveraged transactions; |
• | our capital structure; |
• | an assessment of our management and their experience in identifying operating companies; |
• | general conditions of the securities markets at the time of the initial public offering; and |
• | other factors as were deemed relevant. |
• | higher costs and difficulties inherent in managing cross-border business operations and complying with different commercial and legal requirements of overseas markets; |
• | rules and regulations regarding currency redemption; |
• | complex corporate withholding taxes on individuals; |
• | laws governing the manner in which future business combinations may be effected; |
• | tariffs and trade barriers; |
• | regulations related to customs and import/export matters; |
• | longer payment cycles and challenges in collecting accounts receivable; |
• | tax issues, such as tax law changes and variations in tax laws as compared to the United States; |
• | currency fluctuations and exchange controls; |
• | rates of inflation; |
• | cultural and language differences; |
• | employment regulations; |
• | crime, strikes, riots, civil disturbances, terrorist attacks, natural disasters and wars; |
• | deterioration of political relations with the United States; and |
• | government appropriations of assets. |
• | significantly dilute the equity interest of investors; |
• | subordinate the rights of holders of our common stock if preferred stock is issued with rights senior to those afforded our common stock; |
• | cause a change in control if a substantial number of shares of our common stock is issued, which may affect, among other things, our ability to use net operating loss carry forwards, if any, and could result in the resignation or removal of our present directors and officers; |
• | have the effect of delaying or preventing a change of control of us by diluting the stock ownership or voting rights of a person seeking to obtain control of us; and |
• | adversely affect prevailing market prices for our shares of Class A Common Stock and/or Redeemable Warrants. |
• | default and foreclosure on our assets if our operating revenues after our Initial Business Combination are insufficient to repay our debt obligations; |
• | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
• | our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand; |
• | our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding; |
• | our inability to pay dividends on our common stock; |
• | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available to pay expenses, make capital expenditures and acquisitions, and fund other general corporate purposes; |
• | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
• | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, and execution of our strategy; and |
• | other purposes and other disadvantages compared to our competitors who have less debt. |
• | The Company and the Pershing Square Funds agreed to amend and restate the Forward Purchase Agreement concurrently with the closing of the Proposed IBC, pursuant to which the Forward Purchasers would exercise their right to purchase an aggregate amount of $1.6 billion of Forward Purchase Units ($1.0 billion of Committed Forward Purchase Units and $600 million of Additional Forward Purchase Units). The price per share at which the Pershing Square Funds would have exercised such amended Forward Purchase Agreement would be equal to RemainCo’s (defined below) net asset value at the time of such purchase; |
• | The Company and the Sponsor agreed to amend the Sponsor Warrants concurrently with the closing of the Proposed IBC, such that the Sponsor Warrants would not be exercised or otherwise participate in the Proposed IBC. Instead, they would remain in place, but the exercise price would be adjusted to equal 120% of RemainCo’s net asset value immediately prior to the time it completed its anticipated future business combination with an operating business; and |
• | The Company and its independent directors agreed that the Director Warrants would not be exercised in connection with the Proposed IBC, and would be amended concurrently with the closing of the Proposed IBC. The result of such amendment would have been that, (i) the holders of the Director Warrants would receive shares in the Company in exchange for approximately 72% of the fair market value of the Director Warrants (as determined by a third-party valuation firm), to compensate for the fact that they would not participate in the Proposed IBC as originally envisioned, (ii) such shares would participate in the Distribution and (iii) the roughly 28% of the value of the Director Warrants would remain in place with their exercise price adjusted in the same manner as the exercise price of the Sponsor Warrants as explained above. |
For the Year Ended December 31, 2021 |
For the Period from May 4, 2020 (inception) through December 31, 2020 |
|||||||
Net income/(loss) |
$ | 833,301,124 | $ | (954,881,205 |
) | |||
Less: |
||||||||
Change in fair value of Forward Purchase Agreement liabilities |
598,782,500 | (593,893,320 | ) | |||||
Change in fair value of Outstanding Warrant liabilities |
237,364,758 | (358,644,962 | ) | |||||
Offering costs allocable to Outstanding Warrant liabilities |
- | (912,625 | ) | |||||
Adjusted net loss |
$ (2,846,134 |
) |
$ (1,430,298 |
) |
Name |
Age |
Title | ||
William Ackman |
55 | Chairman and Chief Executive Officer; Director | ||
Ben Hakim |
46 | President | ||
Michael Gonnella |
41 | Chief Financial Officer | ||
Steve Milankov |
48 | Corporate Secretary | ||
Lisa Gersh |
63 | Director | ||
Michael Ovitz |
75 | Director | ||
Jacqueline D. Reses |
52 | Director | ||
Joseph S. Steinberg |
78 | Director |
• | the appointment, compensation, retention, replacement, and oversight of the work of the independent auditors and any other independent registered public accounting firm engaged by us; |
• | pre-approving all audit and permitted non-audit services to be provided by the independent auditors or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures; |
• | reviewing and discussing with the independent auditors all relationships the auditors may have with us in order to evaluate their continued independence; |
• | setting clear hiring policies for employees or former employees of the independent auditors; |
• | setting clear policies for audit partner rotation in compliance with applicable laws and regulations; |
• | obtaining and reviewing a report, at least annually, from the independent auditors describing (i) the independent auditor’s internal quality-control procedures and (ii) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities within the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues; |
• | reviewing and approving any related-party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and |
• | reviewing with management, the independent auditors, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities. |
• | reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation, evaluating our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation; |
• | reviewing and approving on an annual basis the compensation of all other officers; |
• | reviewing on an annual basis our executive compensation policies and plans; |
• | implementing and administering our incentive compensation equity-based remuneration plans; |
• | assisting management in complying with our proxy statement and annual report disclosure requirements; |
• | approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees; |
• | if required, producing a report on executive compensation to be included in our annual proxy statement; and |
• | reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. |
• | identifying, screening and reviewing individuals qualified to serve as directors and recommending to the board of directors candidates for nomination for election at the annual meeting of stockholders or to fill vacancies on the board of directors; |
• | developing and recommending corporate governance guidelines to the board of directors and overseeing the implementation of those guidelines; |
• | coordinating and overseeing the annual self-evaluation of the board of directors, its committees, individual directors and management in the governance of the company; and |
• | reviewing on a regular basis our overall corporate governance and recommending improvements as and when necessary. |
• | Members of our management team are not obligated to devote any specific number of hours to our matters, but they intend to devote as much of their time as they deem necessary to our affairs until we have completed our Initial Business Combination. In addition, we have an investment team comprised of seven members, who are employed by PSCM. While we believe that the investment team members are able to allocate their duties to us and to PSCM amongst themselves in a manner that allows them to provide us with the resources and support we require while fulfilling their responsibilities to PSCM, such persons may have conflicts of interest in allocating his or her time among various business activities. |
• | In the course of their other business activities, our directors and officers may become aware of investment and business opportunities which may be appropriate for presentation to us, as well as the other entities with which they are affiliated. Our management may have conflicts of interest in determining to which entity a particular business opportunity should be presented. |
• | Our Sponsor, directors and officers have agreed to waive their redemption rights with respect to any shares of our Class A Common Stock held by them in connection with the consummation of our Initial Business Combination. If we do not complete our Initial Business Combination within the Combination Period, certain proceeds of the sale of the Sponsor |
Warrants and Director Warrants held in the trust account will be used to fund the redemption of the Public Shares, and the investment opportunity presented by the Sponsor Warrants, the Director Warrants and the Forward Purchase Securities (with respect to the Forward Purchasers and Director Forward Purchasers) will be lost. With certain limited exceptions in each case, our Class B Common Stock and the Forward Purchase Units will not be transferable, assignable or salable and the shares of Class A Common Stock issuable upon conversion or exercise thereof, as applicable, will not be transferable, assignable or salable until 180 days after the consummation of our Initial Business Combination, and the Sponsor Warrants and Director Warrants will not be exercisable, transferable, assignable or salable until three years after the consummation of our Initial Business Combination. Since our Sponsor, directors and officers may directly or indirectly own common stock and warrants, our Sponsor, directors and officers may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our Initial Business Combination. |
• | Our directors and officers may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such directors and officers was included by a target business as a condition to any agreement with respect to our Initial Business Combination. |
• | Our Sponsor, directors or officers may have a conflict of interest with respect to evaluating a business combination and financing arrangements as we may obtain loans from our Sponsor or an affiliate of our Sponsor or any of our directors or officers to finance transaction costs in connection with an intended Initial Business Combination. |
• | the corporation could financially undertake the opportunity; |
• | the opportunity is within the corporation’s line of business; and |
• | it would not be fair to our company and its stockholders for the opportunity not to be brought to the attention of the corporation. |
• | each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock; |
• | each of our directors and executive officers who beneficially owns shares of our common stock; and |
• | all our directors and executive officers as a group. |
Name of Beneficial Owner |
Number of Shares Beneficially Owned |
Percentage of Outstanding Common Stock |
||||||
Directors and Executive Officers: (1) |
||||||||
Pershing Square TH Sponsor, LLC (Our Sponsor) (2) |
100 | * | ||||||
Pershing Square Funds (3)(4) |
200,000,100 | 50.0 | % | |||||
William A. Ackman (5) |
200,000,100 | 50.0 | % | |||||
Ben Hakim |
— | — | ||||||
Michael Gonnella |
4,500 | * | ||||||
Steve Milankov |
— | — | ||||||
Lisa Gersh |
— | — | ||||||
Michael Ovitz (6) |
250,000 | * | ||||||
Jacqueline Reses (7) |
50,000 | * | ||||||
Joseph S. Steinberg (8) |
9,375 | * | ||||||
All directors and executive officers as a group (8 individuals) |
200,313,975 | 50.0 | % | |||||
Other 5% Stockholders: |
||||||||
Guggenheim Capital, LLC (9) |
22,000,000 | 11.0 | % | |||||
Allspring Global Investments Holdings LLC (10) |
11,181,934 | 5.6 | % |
* | Less than one percent |
(1) | Unless otherwise noted, the business address of each of the persons herein is 787 Eleventh Avenue, 9t h Floor, New York, New York 10019. |
(2) | Interests shown consist solely of Class B Common Stock. Such shares will automatically convert into Class A Common Stock on a one-for-one |
(3) | Includes (a) 50,000,000 Committed Forward Purchase Units, (b) 100,000,000 Additional Forward Purchase Units, and (c) 100 shares of Class B Common Stock, which have aggregate voting power equal to 50,000,000 shares of Class A Common Stock, and automatically convert into Class A Common Stock on a one-for-one one-third of one warrant to purchase a share of Class A Common Stock, and the Forward Purchase Units in aggregate are comprised of 150,000,000 shares of Class A Common Stock, and warrants to purchase 50,000,000 shares of Class A Common Stock. The Pershing Square Funds are obligated to purchase the Committed Forward Purchase Units, and may elect to purchase up to the total number of Additional Forward Purchase Units, in one or more private placements to occur no later than simultaneously with our Initial Business Combination. The warrants included in Forward Purchase Units have an exercise price of $23.00 per share and are exercisable upon the later of (i) July 24, 2021 and (ii) 30 days following the consummation of our Initial Business Combination. As of the date of this filing, the Pershing Square Funds have not purchased any Forward Purchase Units. |
(4) | The Pershing Square Funds may be deemed to be the beneficial owners of such securities in their capacity as the Forward Purchasers, and as the members of our Sponsor, and have shared voting and investment power with respect to such securities. |
(5) | Mr. Ackman may be deemed to be the beneficial owner of such securities by virtue of his position as Chief Executive Officer of PSCM, the manager of our Sponsor, as well as the investment advisor to each of Pershing Square Holdings, Ltd., Pershing Square, L.P. and Pershing Square International, Ltd., and as managing member of PS Management GP, LLC, a Delaware limited liability company, as to which voting and investment power is shared. Mr. Ackman disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
(6) | Pursuant to the director forward purchase agreement, Mr. Ovitz has agreed to purchase 250,000 Forward Purchase Units (each of which includes one share of Class A Common Stock). Mr. Ovitz is obligated to purchase such Forward Purchase Units no later than simultaneously with the closing of our Initial Business Combination, and may do so at any time prior thereto at his election. |
(7) | Pursuant to the director forward purchase agreement, Ms. Reses has agreed to purchase 50,000 Forward Purchase Units (each of which includes one share of Class A Common Stock). Ms. Reses is obligated to purchase such Forward Purchase Units no later than simultaneously with the closing of our Initial Business Combination, and may do so at any time prior thereto at her election. |
(8) | Reflects 9,375 shares of Class A Common Stock that Mr. Steinberg purchased through a charity trust—Joseph S. and Diane H. Steinberg Charitable Trust. |
(9) | Based upon the Schedule 13G filed by Guggenheim Partners, LLC with the SEC on August 10, 2020. Beneficial ownership of these shares is shared among Guggenheim Partners, LLC, Guggenheim Capital, LLC and Security Investors LLC. The business address of Guggenheim Partners, LLC is 227 West Monroe Street, Chicago, IL 60606. |
(10) | Based upon the Schedule 13G filed by Allspring Global Investments Holdings LLC with the SEC on January 18, 2022. The business address of Allspring Global Investments Holdings LLC is 525 Market Street, San Francisco, CA, 94105. |
• | whether the terms of the related-party transaction are fair to the Company and whether such terms are no less favorable to the Company than those generally available to an unaffiliated third party under similar circumstances; |
• | whether there are business reasons for the Company to enter into the related-party transaction; |
• | whether the related-party transaction would impair the independence of an outside director; and |
• | whether the related-party transaction would present an improper conflict of interest for any director or executive officer of the Company, taking into account the size of the transaction, the overall financial position of the director, executive officer or related party, the direct or indirect nature of the director’s, executive officer’s or related party’s interest in the transaction, the ongoing nature of any proposed relationship and any other factors the audit committee deems relevant. |
• | Repayment of $1,121,320 (inclusive of accrued interest) in loans made to us by our Sponsor; |
• | Reimbursement for any out-of-pocket |
• | Repayment of any other loans which may be made by our Sponsor or an affiliate of our Sponsor or certain of our directors and officers to finance transaction costs in connection with an intended Initial Business Combination, the terms of which have not been determined, and nor have any written agreements been executed with respect thereto. |
Fee Category |
For the Year ended December 31, 2021 |
For the Period from May 4, 2020 (inception) through December 31, 2020 | ||
Audit Fees (1) |
$ 101,455 | $ 89,301 | ||
Audit- Related Fees (2) |
- | - | ||
Tax Fees (3) |
9,579 | - | ||
All Other Fees |
- | - | ||
Total Fees |
$ 111,034 |
$ 89,301 |
(1) |
Audit Fees 10-Q and other services that an independent registered public accounting firm would customarily provide in connection with regulatory and other required filings submitted to the SEC. |
(2) |
Audit-Related Fees |
(3) |
Tax Fee |
• | the “covered person” was a tax partner, not an audit partner, and did not play any role in the conduct of the audit or provide any other services to us; |
• | the “covered person” was not aware, at the time of purchase and sale, that we were a Marcum audit client; |
• | the “covered person” self-reported the violation when the “covered person” became aware that we were an audit client; |
• | the “covered person” practiced in a different physical office from that in which the lead audit partner primarily practices; |
• | no other Marcum personnel were aware of the transaction until it was self-reported by the “covered person”; and |
• | the amount involved in the covered person’s trade was not material in amount. |
(a) | Financial Statements |
(b) | Financial Statement Schedules. All schedules are omitted for the reason that the information is included in the financial statements or the notes thereto or that they are not required or are not applicable. |
(c) | Exhibits: The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Report. |
* | Filed herewith. |
PERSHING SQUARE TONTINE HOLDINGS, LTD. | ||
By: |
/s/ William A. Ackman | |
Name: William A. Ackman | ||
Title: Chief Executive Officer, Chairman of the Board of Directors |
Name |
Position |
Date | ||
/s/ William A. Ackman William A. Ackman |
Chief Executive Officer, Chairman of the Board of Directors (Principal Executive Officer) |
March 3, 2022 | ||
/s/ Michael Gonnella Michael Gonnella |
Chief Financial Officer (Principal Financial and Accounting Officer) |
March 3, 2022 | ||
/s/ Lisa Gersh Lisa Gersh |
Director |
March 3, 2022 | ||
/s/ Michael Ovitz Michael Ovitz |
Director |
March 3, 2022 | ||
/s/ Jacqueline Reses Jacqueline Reses |
Director |
March 3, 2022 | ||
/s/ Joseph Steinberg Joseph Steinberg |
Director |
March 3, 2022 |
Page |
||||
F-2 |
||||
Financial Statements: |
||||
F-4 |
||||
F-5 |
||||
F-6 |
||||
F-7 |
||||
F-8 |
December 31, |
||||||||
2021 |
2020 |
|||||||
Assets |
||||||||
Current Assets: |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Prepaid expenses |
||||||||
Dividends receivable from operating account |
||||||||
|
|
|
|
|||||
Total Current Assets |
|
|
|
| ||||
Forward Purchase Agreement assets |
||||||||
Cash and marketable securities held in Trust Account |
||||||||
|
|
|
|
|||||
Total Assets |
$ |
$ |
||||||
|
|
|
|
|||||
Liabilities and Stockholders’ Deficit |
||||||||
Current Liabilities: |
||||||||
Accrued expenses |
$ | $ | ||||||
Accrued offering costs |
||||||||
Income taxes payable |
– | |||||||
Due to related party |
|
|
|
|
|
|
– |
|
|
|
|
|
|||||
Total Current Liabilities |
||||||||
Forward Purchase Agreement liabilities |
– | |||||||
Outstanding Warrant liabilities |
||||||||
Deferred underwriting fees payable |
||||||||
|
|
|
|
|||||
Total Liabilities |
||||||||
|
|
|
|
|||||
Commitments and Contingencies |
||||||||
Class A Common Stock, $ value |
||||||||
|
|
|
|
|||||
Stockholders’ Deficit |
||||||||
Preferred stock, $ |
– | |||||||
Class A Common Stock, $ |
– | |||||||
Class B Common Stock, $ |
– | |||||||
Additional paid-in capital |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total Stockholders’ Deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total Liabilities , Class A Common Stock Subject to Possible Redemption and Stockholders’ Deficit |
$ |
$ |
||||||
|
|
|
|
Year Ended |
Period From May 4, 2020 (Inception) Through |
|||||||
December 31, 2021 |
December 31, 2020 |
|||||||
Interest and dividend income |
$ | $ | ||||||
Legal fees |
( |
) | ( |
) | ||||
Insurance |
( |
) | ( |
) | ||||
Printing |
( |
) | ( |
) | ||||
Accounting |
( |
) | ( |
) | ||||
Franchise tax |
( |
) | ( |
) | ||||
Research |
( |
) | ( |
) | ||||
Other |
( |
) | ( |
) | ||||
|
|
|
|
|
|
|
|
|
Loss from operations |
( |
) |
( |
) | ||||
|
|
|
|
|
|
|
|
|
IBC related fee s |
( |
) | ( |
) | ||||
Reimbursement of cancelled IBC |
||||||||
|
|
|
|
|||||
IBC related fees |
( |
) | ||||||
Dividends earned on marketable securities held in Trust Account |
||||||||
Realized gains on marketable securities held in Trust Account |
||||||||
Change in unrealized gains on marketable securities held in Trust Account |
||||||||
|
|
|
|
|||||
Income earned in Trust Account |
||||||||
Offering costs allocable to Outstanding Warrant liabilities |
( |
) | ||||||
Change in fair value of Forward Purchase Agreement liabilities/assets |
( |
) | ||||||
Change in fair value of Outstanding Warrant liabilities |
( |
) | ||||||
|
|
|
|
|||||
Other income/(loss) |
( |
) | ||||||
|
|
|
|
|||||
Income/(loss) before income tax provision |
( |
) | ||||||
Income tax provision |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net income/(loss) |
$ |
$ |
( |
) | ||||
|
|
|
|
|||||
Basic weighted-average shares outstanding, Class A Common Stock subject to possible redemption |
||||||||
|
|
|
|
|||||
Basic net income per share, Class A Common Stock subject to possible redemption |
$ | $ | ||||||
|
|
|
|
|||||
Diluted weighted-average shares outstanding, Class A Common Stock subject to possible redemption |
||||||||
|
|
|
|
|||||
Diluted net income per share, Class A Common Stock subject to possible redemption |
$ | $ | ||||||
|
|
|
|
|||||
Basic and diluted weighted-average shares outstanding, Non-redeemable Class B Common Stock |
||||||||
|
|
|
|
|||||
Basic net income/(loss) per share, Non-redeemable Class B Common Stock |
$ | $ | ( |
) | ||||
|
|
|
|
|||||
Diluted net income/(loss) per share, Non-redeemable Class B Common Stock |
$ | $ | ( |
) | ||||
|
|
|
|
Common Stock |
Additional Paid-In Capital |
Accumulated Deficit |
Total Stockholders’ Deficit |
|||||||||||||||||||||||||
Class A |
Class B |
|||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
Balance – May 4, 2020 (inception) |
$ | $ | $ | $ | $ | |||||||||||||||||||||||
Issuance of Class B Common Stock to Sponsor |
||||||||||||||||||||||||||||
Measurement adjustment on redeemable common stock |
( |
) | ( |
) | ||||||||||||||||||||||||
Net loss |
( |
) | ( |
) | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance – December 31, 2020 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) | |||||||||||||||||||
Measurement adjustment on redeemable common stock |
– | – | ( |
) | ( |
) | ||||||||||||||||||||||
Net income |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance – December 31, 2021 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2021 |
Period From May 4, 2020 (Inception) Through December 31, 2020 |
|||||||
Cash flows from operating activities: |
||||||||
Net income/(loss) |
$ | $ | ( |
) | ||||
Adjustments to reconcile net income/(loss) to net cash used in operating activities: |
||||||||
Offering costs allocable to Outstanding Warrant liabilities |
||||||||
Change in fair value of Forward Purchase Agreement liabilities/assets |
( |
) | ||||||
Change in fair value of Outstanding Warrant liabilities |
( |
) | ||||||
Dividends earned on marketable securities held in Trust Account |
( |
) | ( |
) | ||||
Realized gains on marketable securities held in Trust Account |
( |
) | ( |
) | ||||
Change in unrealized gains on marketable securities held in Trust Account |
( |
) | ( |
) | ||||
Changes in operating assets and liabilities: |
||||||||
Dividends receivable from operating account |
( |
) | ||||||
Prepaid expenses |
( |
) | ||||||
Accrued expenses |
||||||||
Income taxes payable |
( |
) | ||||||
Due to related party |
– |
|||||||
Net cash used in operating activities |
( |
) |
( |
) | ||||
Cash flows from investing activities: |
||||||||
Investment of cash in Trust Account |
( |
) | ||||||
Cash withdrawn from Trust Account to pay income taxes |
||||||||
Net cash provided by/(used in) investing activities |
( |
) | ||||||
Cash flows from financing activities: |
||||||||
Proceeds from sale of Units |
– | |||||||
Proceeds from sale of Sponsor and Director Warrants |
– | |||||||
Payment of underwriting fees |
– | ( |
) | |||||
Payment of offering costs |
( |
) | ( |
) | ||||
Proceeds from promissory note – related party |
– | |||||||
Repayment of promissory note – related party |
– | ( |
) | |||||
Proceeds from issuance of Class B Common Stock to Sponsor |
– | |||||||
Net cash provided by financing activities |
( |
) |
||||||
Net change in cash |
( |
) | ||||||
Cash and cash equivalents – beginning of period |
||||||||
Cash and cash equivalents – end of period |
$ |
$ |
||||||
Supplemental disclosure of cash flow information: |
||||||||
Cash paid for income taxes |
$ | ( |
) | $ | ||||
Supplemental disclosure of non-cash activities: |
||||||||
Deferred underwriting fees payable |
$ | $ | ||||||
Initial classification of common stock subject to possible redemption |
$ | – | $ | |||||
Change in value of common stock subject to possible redemption |
$ | $ | ||||||
Year Ended December 31, 2021 |
Period From May 4, 2020 (Inception) through December 31, 2020 |
|||||||||||||||
(Basic) |
(Diluted) |
(Basic) |
(Diluted) |
|||||||||||||
Class A Common Stock Subject to Possible Redemption |
| |||||||||||||||
Numerator: Earnings allocable to Class A Common Stock subject to possible redemption |
| |||||||||||||||
Income earned in Trust Account |
$ |
$ |
$ |
$ |
||||||||||||
Income taxes |
( |
( |
( |
( |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net earnings |
$ |
$ |
$ |
$ |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Denominator: Weighted-average Class A Common Stock subject to possible redemption |
| |||||||||||||||
Weighted-average shares outstanding, Class A Common Stock subject to possible redemption |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net income per share, Class A Common Stock subject to possible redemption |
$ |
$ |
$ |
$ |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Non-Redeemable Class B Common Stock |
||||||||||||||||
Numerator: Net income/(loss) minus net earnings and change in fair value of FPA assets/liabilities |
| |||||||||||||||
Net income/(loss) |
$ |
$ |
$( |
$( |
||||||||||||
Net earnings allocable to Class A Common Stock subject to possible redemption |
( |
( |
( |
( |
||||||||||||
Change in fair value of FPA assets/liabilities |
( |
|||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Non-redeemable net income/(loss) |
$ |
$ |
$( |
$( |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Denominator: Weighted-average Non-redeemable Class B Common Stock |
|
|||||||||||||||
Weighted-average shares outstanding, Non-redeemable Class B Common Stock |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net income/(loss) per share, Non-redeemable Class B Common Stock |
$ |
$ |
$( |
$( |
||||||||||||
|
|
|
|
|
|
|
|
• | The Company and the Pershing Square Funds agreed to amend and restate the Forward Purchase Agreement concurrently with the closing of the Proposed IBC, pursuant to which the Forward Purchasers would exercise their right to purchase an aggregate amount of $ |
• | The Company and the Sponsor agreed to amend the Sponsor Warrants concurrently with the closing of the Proposed IBC, such that the Sponsor Warrants would not be exercised or otherwise participate in the Proposed IBC. Instead, they would remain in place, but the exercise price would be adjusted to equal |
• | The Company and its independent directors agreed that the Director Warrants would not be exercised in connection with the Proposed IBC, and would be amended concurrently with the closing of the Proposed IBC. The result of such amendment would have been that, (i) the holders of the Director Warrants would receive shares in the Company in exchange for approximately |
• | in whole and not in part; |
• | at a price of $ |
• | upon a minimum of |
• | if, and only if, the daily volume-weighted average price of the Class A Common Stock equals or exceeds $ |
• | in whole and not in part; |
• | at $ |
• | upon a minimum of |
• | if, and only if, the daily volume-weighted average price of the Class A Common Stock equals or exceeds $ |
Level 1: |
Valuation determined based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. | |
Level 2: |
Valuation determined based on observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. | |
Level 3: |
Valuation determined based on unobservable inputs on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability. |
December 31, |
||||||||||
Description |
Level |
2021 |
2020 |
|||||||
Assets: |
||||||||||
Cash and marketable securities held in Trust Account |
1 | $ | $ | |||||||
Committed Forward Purchase Agreement Asset |
3 | – | ||||||||
Liabilities: |
||||||||||
Outstanding Warrants Liability – Public Warrants |
1 | |||||||||
Outstanding Warrants Liability – Private Placement Warrants |
3 | |||||||||
Committed Forward Purchase Agreement Liability |
|
3 |
|
|
– |
|
|
|
|
|
Additional Forward Purchase Agreement Liability |
3 |
December 31, |
||||||||
Inputs – Private Placement Warrants |
2021 |
2020 |
||||||
Strike Price |
$ |
$ |
||||||
Risk-Free Interest Rate |
||||||||
Observed Stock Price |
$ |
$ |
||||||
Public Warrant Price |
$ |
$ |
||||||
Term (Years) |
||||||||
Volatility |
||||||||
Illiquidity Discount |
||||||||
Probability of Warrant Renegotiation |
December 31, |
||||||||
Inputs – Forward Purchase Agreements |
2021 |
2020 |
||||||
Exercise Price |
$ |
$ |
||||||
Risk-Free Interest Rate |
||||||||
Observed Stock Price |
$ |
$ |
||||||
Public Warrant Price |
$ |
$ |
||||||
Term (Years) |
||||||||
Discount for Lack of Marketability – Committed FPA |
||||||||
Discount for Lack of Marketability – Additional FPA |
||||||||
Discount for Probability of Exercise – Additional FPA |
Outstanding Warrants Liability |
Public Warrants |
Private Placement Warrants |
Total Outstanding Warrants |
|||||||||
Fair Value at May 4, 2020 (inception) |
$ | $ | $ | |||||||||
Initial Measurement |
||||||||||||
Change in Fair Value |
||||||||||||
|
|
|
|
|
|
|||||||
Fair Value at December 31, 2020 |
||||||||||||
Change in Fair Value |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Fair Value at December 31, 2021 |
$ |
$ |
$ |
|||||||||
|
|
|
|
|
|
FPA Liability / (Asset) |
Committed Forward Purchase Agreement |
Additional Forward Purchase Agreement |
Total Forward Purchase Agreements |
|||||||||
Fair Value at May 4, 2020 (inception) |
$ | $ | $ | |||||||||
Initial Measurement |
– | – | – | |||||||||
Change in Fair Value |
||||||||||||
|
|
|
|
|
|
|||||||
Fair Value at December 31, 2020 – Liability |
||||||||||||
Change in Fair Value |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Fair Value at December 31, 2021 – Liability / (Asset) |
$ | ( |
) |
$ | $ | ( |
) | |||||
|
|
|
|
|
|
December 31, |
||||||||
2021 |
2020 |
|||||||
Deferred tax assets: |
||||||||
Startup expenses / Organizational costs |
$ | $ | ||||||
Total deferred tax assets |
||||||||
Valuation Allowance |
( |
) | ( |
) | ||||
Deferred tax liabilities: |
||||||||
Unrealized gains on marketable securities |
( |
) | ( |
) | ||||
Total deferred tax liabilities |
( |
) | ( |
) | ||||
Net deferred tax asset, net of allowance |
$ | $ |
December 31, |
||||||||
2021 |
2020 |
|||||||
Current |
||||||||
Federal |
$ | $ | ||||||
State |
||||||||
Deferred |
||||||||
Federal |
( |
) | ( |
) | ||||
State |
||||||||
Change in valuation allowance |
||||||||
Income tax provision |
$ | $ | ||||||
|
|
|
|
|
|
|
|
|
December 31, | ||||
2021 |
2020 | |||
Statutory federal income tax rate |
||||
State taxes, net of federal tax benefit |
||||
Change in fair value of Forward Purchase Agreement liabilities |
( |
( | ||
Change in fair value of Outstanding Warrant liabilities |
( |
( | ||
Offering costs allocable to Outstanding Warrant liabilities |
( | |||
Change in valuation allowance |
( | |||
|
| |||
Income tax provision |
( |
( | ||
|
|